Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
Steenackers K, Hanning N, Bruckers L, Desombere I, Marchant A, Ariën KK, Georges D, Soentjens P, D'Onofrio V, Hites M, Berens-Riha N, De Coster I, Damme PV. Steenackers K, et al. Among authors: de coster i. Vaccine. 2024 Nov 14;42(25):126117. doi: 10.1016/j.vaccine.2024.07.018. Epub 2024 Jul 16. Vaccine. 2024. PMID: 39019657 Free article. Clinical Trial.
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade.
Moore KA, Ostrowsky JT, Mehr AJ, Johnson RA, Ulrich AK, Moua NM, Fay PC, Hart PJ, Golding JP, Benassi V, Preziosi MP, Adetifa IM, Akpede GO, Ampofo WK, Asogun DA, Barrett ADT, Bausch DG, de Coster I, Emperador DM, Feldmann H, Fichet-Calvet E, Formenty PBH, Garry RF, Grant DS, Günther S, Gupta SB, Jaspard M, Mazzola LT, Okogbenin SA, Roth C, Schmaljohn CS, Osterholm MT. Moore KA, et al. Among authors: de coster i. Lancet Infect Dis. 2024 Nov;24(11):e696-e706. doi: 10.1016/S1473-3099(24)00229-9. Epub 2024 Jul 1. Lancet Infect Dis. 2024. PMID: 38964363 Review.
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.
Yeh MT, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, Weiner AJ, Bandyopadhyay AS, Van Damme P, De Coster I, Revets H, Macadam A, Andino R. Yeh MT, et al. Among authors: de coster i. Cell Host Microbe. 2020 May 13;27(5):736-751.e8. doi: 10.1016/j.chom.2020.04.003. Epub 2020 Apr 23. Cell Host Microbe. 2020. PMID: 32330425 Free PMC article. Clinical Trial.
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, Modlin J, Clemens R, Costa Clemens SA, Bachtiar NS, Van Damme P. De Coster I, et al. Among authors: de smedt p. Lancet. 2021 Jan 2;397(10268):39-50. doi: 10.1016/S0140-6736(20)32541-1. Epub 2020 Dec 9. Lancet. 2021. PMID: 33308429 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
Erdem R, De Coster I, Withanage K, Mercer LD, Marchant A, Taton M, Cools N, Lion E, Cassels F, Higgins D, Ivinson K, Locke E, Mahmood K, Wright PF, Gast C, White JA, Ackerman ME, Konopka-Anstadt JL, Mainou BA, Van Damme P. Erdem R, et al. Among authors: de coster i. Vaccine. 2023 Mar 3;41(10):1657-1667. doi: 10.1016/j.vaccine.2023.01.048. Epub 2023 Feb 4. Vaccine. 2023. PMID: 36746739 Free PMC article. Clinical Trial.
Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A. van Damme P, et al. Among authors: de coster i. PLoS One. 2011;6(9):e25398. doi: 10.1371/journal.pone.0025398. Epub 2011 Sep 30. PLoS One. 2011. PMID: 21980445 Free PMC article. Clinical Trial.
Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.
Leroux-Roels G, Cramer JP, Mendelman PM, Sherwood J, Clemens R, Aerssens A, De Coster I, Borkowski A, Baehner F, Van Damme P. Leroux-Roels G, et al. Among authors: de coster i. J Infect Dis. 2018 Jan 30;217(4):597-607. doi: 10.1093/infdis/jix572. J Infect Dis. 2018. PMID: 29140444 Free PMC article. Clinical Trial.
26 results